Personalis Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.4%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$82.5Mnext fiscal year
FY EPS (est.)
-$1.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Clinical Test Volume Quarterly7.8KTarget: 43,000 - 45,000 tests
Clinical Test Revenue Quarterly1.4MTarget: $10.0 million - $11.0 million
Total Strategic Revenue (Clinical + Biopharma MRD) Quarterly4.5MTarget: $30.0 million - $32.0 million
Total Company Revenue Quarterly15.5MTarget: $78.0 million - $80.0 million
Watch Items
- Medicare Reimbursement Coverage DecisionsTrigger: Securing additional MolDX coverage decisions for NeXT Personal across new solid tumor indicationsAction: Monitor CMS/MolDX registry updates and company press releases following clinical data presentations
- Cash Burn and Liquidity RunwayTrigger: Annual cash usage exceeding $100.0 million or cash balance falling below $150.0 millionAction: Evaluate the utilization of the at-the-market (ATM) equity program and assess potential dilution risks
- Biopharma MRD Revenue AccelerationTrigger: Full-year biopharma MRD revenue tracking below the $20.0 million - $21.0 million targetAction: Review quarterly biopharma contract wins and partnership expansions, particularly with key players like Tempus
Research as of 19 Jun 2026